Addressing GLP-1 Related Skin Laxity with Sofwave: An FDA Cleared, Non-Invasive Solution for Face and Body
The rapid rise in GLP-1 medication has fundamentally shifted the aesthetic treatment landscape. As more patients experience significant and sustained weight loss, practitioners are increasingly encountering a new set of concerns centred on skin laxity, reduced firmness and changes in muscle tone across both face and body. While pharmacological weight loss delivers clear metabolic benefits, it also accelerates volume reduction in the skin and underlying support structures. This has created growing demand for tightening solutions that can restore skin quality and support tissue firmness without adding risk, downtime or further volume loss. At the forefront of this evolving clinical need is Sofwave, an FDA-cleared¹, ultrasound-based skin-lifting technology designed to deliver predictable, non-invasive lifting and tightening outcomes across the face and body.
A shifting treatment paradigm post GLP-1
